DV
Dividend Vision

IMUX — Immunic Inc

Immunic Inc (IMUX)

Total return is -99.7% over the past 12.3 years, 511.5 points behind SPY at 411.8%. Its deepest 1-year drawdown was 47.9%.

This is a single-stock equity holding in Immunic Inc, a biopharmaceutical company, rather than a diversified ETF. The holding does not currently pay distributions and lacks available data on expense ratio and assets under management. This equity position appeals primarily to investors seeking exposure to the biotech sector and potential capital appreciation rather than current income.

IMUX key facts

Asset type
Stock
Asset class
Equity
Inception date
04/17/2014
Last close
$16.06
Market cap
$204,322,240
Average volume
79700.0
Payment date
04/15/2019
Beta
1.375
Payout ratio
0.0
Forward P/E
0.0
EPS
$-4.72